Diamyd Medical

7,77

SEK

-1,65 %

Mindre end 1K følgere

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-1,65%

-6,05%

-55,52%

-52,22%

-39,3%

-34%

-49,97%

-59,74%

+160,36%

Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.

Markedsværdi

1,01 mia. SEK

Aktieomsætning

7,98 mio. SEK

Omsætning

130 t

EBIT %

-112.746,15 %

P/E

-

Udbytteafkast, %

-

Finanskalender

25.6

2025

Delårsrapport Q3'25

8.10

2025

Årsrapport '25

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelsefor 20 timer siden

Diamyd Medical AB: Last day of the subscription period in Diamyd Medicals rights issue

Selskabsmeddelelsefor 21 timer siden

Diamyd Medical AB: Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes

Selskabsmeddelelse25.4.2025, 12.00

Diamyd Medical AB: Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears second-to-last safety review ahead of early readout in March 2026

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse24.4.2025, 06.30

Carnegie Access: Diamyd Medical: Intervju - Statusuppdatering

Selskabsmeddelelse22.4.2025, 12.05

Diamyd Medical AB: Shareholders in Diamyd Medical, including the Chairman of the Board, have provided additional subscription commitments in the ongoing rights issue

Selskabsmeddelelse21.4.2025, 09.00

Diamyd Medical AB: Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout

Selskabsmeddelelse17.4.2025, 07.30

Diamyd Medical AB: The prevention trial DiaPrecise with Diamyd® clears first safety milestone

Selskabsmeddelelse15.4.2025, 15.45

Diamyd Medical AB: Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment

Selskabsmeddelelse14.4.2025, 11.10

Diamyd Medical AB: Diamyd Medical publishes prospectus with regards to the rights issue

Pressemeddelelse9.4.2025, 17.07

Carnegie Access: Diamyd Medical: Steady progression towards major inflection point – Q2 review

Selskabsmeddelelse9.4.2025, 06.15

Diamyd Medical AB: Quarterly Report 2 24/25

Selskabsmeddelelse21.3.2025, 11.10

Diamyd Medical AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue

Pressemeddelelse20.3.2025, 05.21

Carnegie Access: Diamyd Medical: Aiming for GMP certification in 2025

Selskabsmeddelelse19.3.2025, 13.40

Diamyd Medical AB: Diamyd Medical plans for GMP Certification in 2025

Selskabsmeddelelse17.3.2025, 12.45

Diamyd Medical AB: Diamyd Medical highlights clinical benefits of C-peptide preservation at ATTD 2025

Selskabsmeddelelse13.3.2025, 13.25

Diamyd Medical AB: Diamyd Medical advances AI-powered screening for Type 1 Diabetes within the ASSET Project

Selskabsmeddelelse10.3.2025, 07.45

Diamyd Medical AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue

Selskabsmeddelelse28.2.2025, 13.45

Diamyd Medical AB: The Board of Directors in Diamyd Medical has resolved on a rights issue of approximately SEK 208 million

Selskabsmeddelelse20.2.2025, 15.15

Diamyd Medical AB: Diamyd Medical precision medicine patent for prevention and treatment of autoimmune diabetes to be granted in Mexico

Selskabsmeddelelse18.2.2025, 10.40

Diamyd Medical AB: Diamyd[ ]Medical's CFO to leave in 2025

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.